Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies
- PMID: 15654906
- DOI: 10.1111/j.1600-0609.2004.00360.x
Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies
Abstract
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) from human leukocyte antigen (HLA)-compatible sibling donors is a potential curative treatment for hematological and non-hematological malignancies. Nevertheless, high mortality rates may be associated with this therapy, especially in older patients, those with other comorbidities or who receive a second HSCT.
Patients and methods: We analyzed the factors associated with transplant-related mortality (TRM) and overall survival in 157 consecutive adult patients (104 males and 53 females) who received a HSCT [29 bone marrow (BM) transplantation and 128 peripheral blood (PB) transplantation] from a HLA-identical sibling between January 1995 and March 2002 in our institution. One hundred patients received a standard conditioning prior to HSCT (STAND) and 57 patients received a reduced-intensity conditioning (RIC) HSCT. Fifty-eight patients were in an early phase at transplant and 99 in a non-early phase. Median age was 46 yr (16-66), and 90 patients (57%) were >45 yr of age.
Results: Patients in the RIC group were older than those in the STAND group, and had a higher proportion of non-early disease phases including a prior autologous HSCT in 39%. Median follow-up for survivors was 28 and 15 months in the STAND and RIC groups (P < 0,001), respectively. Cumulative incidence of TRM at 2 yr was 30% [95% confidence interval (CI) 22-41%] for the STAND group and 22% (95% CI 13-37%) for the RIC group [non-significant (NS)]. Factors associated with a higher TRM in multivariate analysis were: STAND vs. RIC conditioning regimen [relative risk (RR) 5.4; 95% CI 2.3-12.8; P < 0.001]; age > or =45 yr vs. <45 yr (RR 5; 95% CI 2.4-10.8, P < 0.001); second vs. first HSCT (RR 2.8, 95% CI 1.3-6.3, P = 0.01) and non-T-cell-depleted vs. T-cell-depleted graft (RR 2.7, 95% CI 1.3-5.8, P = 0.009). Overall survival (OS) at 2 yr was 52.5 +/- 10.4% for STAND group and 59 +/- 16.8% in RIC group. Factors associated with poorer OS in multivariate analysis were: STAND vs. RIC conditioning regimen (RR 3.4, 95% CI 1.7-6.9, P = 0.001); age > or =45 vs <45 yr (RR 2.5, 95% CI 1.4-4.5, P = 0.002) and diagnosis [other than chronic myeloid leukemia (CML) vs. CML] (RR 2.6, 95% CI 1.2-5.7 P = 0.02).
Conclusions: Our results indicate that the introduction of RIC allogeneic HSCT for patients at high risk for TRM (advanced age, prior HSCT and non-T-cell depletion) leads to a reduction in the TRM and improvement in the OS.
(c) Blackwell Munksgaard 2005
Similar articles
-
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.Biol Blood Marrow Transplant. 2008 Jun;14(6):651-7. doi: 10.1016/j.bbmt.2008.03.006. Biol Blood Marrow Transplant. 2008. PMID: 18489990
-
Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.Bone Marrow Transplant. 2002 Jul;30(2):63-8. doi: 10.1038/sj.bmt.1703606. Bone Marrow Transplant. 2002. PMID: 12132043 Clinical Trial.
-
Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.Haematologica. 2002 Jan;87(1):52-8. Haematologica. 2002. PMID: 11801465
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.Crit Rev Oncol Hematol. 2004 Sep;51(3):171-89. doi: 10.1016/j.critrevonc.2004.05.008. Crit Rev Oncol Hematol. 2004. PMID: 15331077 Review.
Cited by
-
The EBMT Risk Score in the Presence of Graft Versus Host Disease in Allogeneic Stem Cell Transplantation in Adult Acute Myelogenous Leukemia: A Multistate Model for Competing Risks.Int J Hematol Oncol Stem Cell Res. 2014 Jul 1;8(3):1-11. Int J Hematol Oncol Stem Cell Res. 2014. PMID: 25642302 Free PMC article.
-
Graft-versus-leukemia effect of nonmyeloablative stem cell transplantation.Korean J Intern Med. 2009 Dec;24(4):287-98. doi: 10.3904/kjim.2009.24.4.287. Epub 2009 Nov 27. Korean J Intern Med. 2009. PMID: 19949725 Free PMC article. Review.
-
Fludarabine, busulfan, and melphalan conditioning regimen in allogeneic hematopoietic stem cell transplantation for adult patients with myeloid malignancies: A multicenter retrospective study.EJHaem. 2024 Jul 8;5(4):757-767. doi: 10.1002/jha2.947. eCollection 2024 Aug. EJHaem. 2024. PMID: 39157627 Free PMC article.
-
Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning.J Korean Med Sci. 2007 Apr;22(2):227-34. doi: 10.3346/jkms.2007.22.2.227. J Korean Med Sci. 2007. PMID: 17449929 Free PMC article. Clinical Trial.
-
Differential susceptibility of C57BL/6NCr and B6.Cg-Ptprca mice to commensal bacteria after whole body irradiation in translational bone marrow transplant studies.J Transl Med. 2008 Feb 28;6:10. doi: 10.1186/1479-5876-6-10. J Transl Med. 2008. PMID: 18307812 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous